17:50 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and mouse studies suggest a peptide-based agent that captures Aβ42 and induces autophagy could help treat AD. The “nanosweeper” agent consists of a PEGylated GKLVFF peptide that binds Aβ42 linked...
22:03 , May 10, 2018 |  BC Extra  |  Preclinical News

‘Nanosweepers’ could degrade beta amyloid to treat Alzheimer’s

Researchers at Beijing’s National Center for Nanoscience and Technology and colleagues published a paper in Nature Communications describing a self-destructive "nanosweeper" based on multifunctional peptide-polymers that improved memory deficits after capturing and degrading extracellular deposits...
17:36 , May 4, 2018 |  BC Week In Review  |  Clinical News

Merck's verubecestat reduces beta amyloid levels but fails to improve cognition, function

Data published in the New England Journal of Medicine from the discontinued Phase II/III EPOCH trial in 1,958 patients with mild to moderate Alzheimer's disease showed that verubecestat (MK-8931) from Merck & Co. Inc. (NYSE:MRK)...
17:11 , Feb 6, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cell-free assays; plasma markers A composite measure of Aβ40, Aβ42 and APP669-711 levels in plasma that determines the brain burden of β amyloid could help stratify AD and MCI patients in clinical trials. In plasma...
22:50 , Feb 2, 2018 |  BC Extra  |  Preclinical News

Plasma biomarker may aid AD diagnosis

In a study published in Nature, Japanese researchers identified a plasma biomarker of brain beta amyloid burden that had an accuracy of about 90% compared against PET imaging, offering the possibility of cheaper and less...
20:54 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Mouse studies suggest antisense oligonucleotides (ASOs) targeting the APOE variant APOE4 could help treat AD. In a mouse model of AD, intracerebroventricular injection of an ASO targeting APOE4 decreased β amyloid plaque...
15:34 , Apr 26, 2017 |  BC Extra  |  Clinical News

Alzheon identifies MOA for AD candidate

In a paper published in CNS Drugs, researchers from Alzheon Inc. (Framingham, Mass.) identified the mechanism of action for tramiprosate, the active agent in its Alzheimer's disease candidate ALZ-801. The paper showed that the compound...
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
04:28 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

PF-06648671: Ph I data

A double-blind, placebo-controlled, Belgian Phase I trial in 92 healthy volunteers showed that single doses of 150 and 300 mg oral PF-06648671 and once-daily doses of 4-200 mg oral PF-06648671 for 14 days were well...
03:37 , Dec 17, 2016 |  BioCentury  |  Product Development

Not dead yet

The amyloid hypothesis may not be dead, but positive Phase Ib data for Biogen Inc.’s aducanumab notwithstanding, the preponderance of evidence still suggests that attacking plaques is unlikely to be an effective intervention for Alzheimer’s...